InvestorsHub Logo
Followers 30
Posts 1939
Boards Moderated 0
Alias Born 01/11/2011

Re: skydog526 post# 123112

Monday, 08/25/2014 1:09:07 PM

Monday, August 25, 2014 1:09:07 PM

Post# of 403252
http://www.elitepharma.com/investor_relations.asp?goto=378

Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200

“Following the success of the pilot bioequivalence study in December for ELI-201, we are delighted with the results of this pivotal bioequivalence clinical study for ELI-200, our second opioid abuse deterrent product. ELI-200 is expected to be filed this year and will be the first NDA product filed by Elite with the U.S. Food and Drug Administration.”


http://www.elitepharma.com/investor_relations.asp?goto=377

Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201

"We are delighted with the results from our clinical studies and pleased to have confirmation of the formulation for our extended release product, ELI-201, our twice-daily oxycodone product and the progress of the second opioid,"

"This is our year!"

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News